Primary Outcome Measures
Disease free survival (DFS) [Time Frame: From randomization to first event (relapse, second malignancy, or death in complete remission) or time to last follow-up for patients without events, assessed up to 3 years] [Designated as safety issue: ]
Secondary Outcome Measures
Imatinib mesylate administration after allogeneic hematopoietic stem cell transplantation (HSCT) in high risk Ph+ ALL patients [Time Frame: Up to 2 years] [Designated as safety issue: ]
Event free survival (EFS) of high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate [Time Frame: From the date of bone marrow for minimal residual disease (MRD) assessment at end-IB to first event or time to last follow-up for patients without events, assessed up to 3 years] [Designated as safety issue: ]
Incidence of grade 3 or higher infections in standard risk Ph+ ALL patients in the two randomized arms [Time Frame: Up to 3 years] [Designated as safety issue: ]
EFS of all enrolled patients [Time Frame: From enrollment until the first occurrence of: M3 marrow at the end of Induction IA, relapse, second malignancy, or death as a first event, assessed up to 3 years] [Designated as safety issue: ]
Overall survival (OS) of all enrolled patients [Time Frame: From study enrollment to death from any cause, assessed up to 3 years] [Designated as safety issue: ]
OS of standard risk patients [Time Frame: From randomization to death from any cause, assessed up to 3 years] [Designated as safety issue: ]
OS of high risk patients [Time Frame: From the date of MRD assessment at end-IB to death from any cause, assessed up to 3 years] [Designated as safety issue: ]